Highest-materiality recent filing
Janux Q1 2026 net loss $24.4M; cash $956.4M; discontinues JANX008, initiates JANX014
Net loss of $24.4M for Q1 2026 vs $23.5M YoY; cash and investments at $956.4M.
Janux reclassifies director Eric Dobmeier from Class III to Class II to rebalance board classes
On April 28, 2026, Eric Dobmeier resigned as Class III director and immediately reappointed as Class II director.
Janux reports FY2025 net loss $113.6M; cash $966.6M; BMS collaboration with $50M upfront
Cash and short-term investments $966.6M at Dec 31, 2025, down from $1.03B a year ago.
Janux licenses tumor-activated therapeutic to BMS for solid tumors; up to $800M milestones
Upfront $15M and near-term milestone $35M; total milestones up to ~$800M.
Janux Q3 2025 net loss narrows to $24.3M; cash at $989M; trial enrollment continues
Net loss of $24.3M improved from $28.1M in Q3 2024; R&D expense rose to $34.6M from $18.6M.
Janux Therapeutics CSO Byron Robinson departs effective Sept 18, 2025
Byron Robinson, Ph.D., Chief Strategy Officer, departed Janux effective September 18, 2025.
Janux Q2 net loss $33.9M; cash $996M; Merck milestone $10M triggered
Cash and short-term investments $996.0M at June 30, 2025, vs $1.03B at Dec 31, 2024.
Janux Therapeutics shareholders elect three Class I directors, ratify EY
David Campbell, Ron Barrett, and Winston Kung elected Class I directors with >42M votes each.
Janux Q1 net loss $23.5M; initiates JANX007 Phase 1b expansion in mCRPC
Initiated Phase 1b expansion with JANX007 in taxane-naïve mCRPC; updated median rPFS 7.5 months (n=16).
Janux Therapeutics reports FY2024 net loss $69M, cash $1.03B, positive JANX007 data
Cash and short-term investments $1.03B at year-end 2024, up from $344M in 2023, largely from $402.5M December offering.
Janux Therapeutics prices $350M public offering of common stock and pre-funded warrants
Priced 5,317,460 shares at $63.00/share and pre-funded warrants for 238,095 shares at $62.999
Janux reports positive interim JANX007 data; selects doses for Phase 1b expansion in mCRPC
100% of 16 patients achieved PSA50 declines; 63% PSA90; 31% PSA99 declines.
Janux reports Q3 net loss $28.1M; cash $658M; JANX007 update expected by year-end
Cash and short-term investments $658.0M at Sept 30, 2024 vs $344.0M at Dec 31, 2023.
Janux Q2 2024 net loss $6.0M; cash $646.3M; receives $7.5M Merck milestone
Net loss of $6.0M vs $17.5M in Q2 2023; improvement driven by $7.5M milestone payment from Merck.
Jay Lichter, Ph.D. resigned from the board effective July 19, not due to any disagreement.
Janux shareholders elect three Class III directors and ratify EY as auditor
Class III directors elected: Vickie Capps, Jay Lichter, and Jake Simson, each with >41 million votes for.
Janux Therapeutics Q1 2024: Cash $651.8M; net loss $14.8M; trials ongoing
Cash and short-term investments $651.8M as of March 31, 2024, up from $344.0M at Dec 31, 2023.
Janux reports $344M year-end cash; Q4 net loss $11.8M; positive Phase 1 JANX007/JANX008 data
Year-end cash & investments $344M; net loss $58.3M for FY 2023 vs $63.1M in 2022.
Janux Therapeutics prices $296.5M public offering of common stock and pre-funded warrants
Pricing: 4,440,851 shares at $46.50/share and pre-funded warrants to purchase 1,935,483 shares at $46.499.
Janux Therapeutics suspends ATM equity offering program
Delivered written notice to BofA on Feb 28, 2024 suspending the ATM prospectus supplement.
In connection with Dr. Lichter’s resignation, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Governance Committee”), Ron Barrett, Ph.D. was appointed as Chair of the Board.
On July 19, 2024, Jay Lichter, Ph.D. resigned as a member of the Board of Directors (the “Board”) of Janux Therapeutics, Inc. (the “Company”), including his chairmanship of the Board, effective as of such date.
On July 19, 2024, the Board, upon the recommendation of the Nominating and Governance Committee, appointed (i) Natasha Hernday as a Class II director of the Company, with a term of office expiring at the Company’s 2026 annual meeting of stockholders, or until her earlier death, resignation or removal.
and (ii) Eric Dobmeier as a Class III director of the Company, with a term of office expiring at the Company’s 2027 annual meeting of stockholders, or until his earlier death, resignation or removal.
Max materiality 0.90 · Median 0.65 · Most common event earnings